# Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

> **NCT04248192** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Catherine Bollard** · enrollment: 8 (estimated)

## Conditions studied

- HIV-Infected Individuals

## Interventions

- **BIOLOGICAL:** DD HST-NEETs

## Key facts

- **NCT ID:** NCT04248192
- **Lead sponsor:** Catherine Bollard
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-01
- **Primary completion:** 2025-09
- **Final completion:** 2026-04
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04248192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04248192, "Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04248192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*